Solid Biosciences Inc. (SLDB) |
|
6.36 0.11 (1.76%)
|
06-06 15:26 |
|
Open: |
6.25 |
Pre. Close: |
6.25 |
|
High:
|
6.36 |
Low:
|
6.16 |
|
Volume:
|
6,294 |
Market Cap:
|
125(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 3:21:43 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 7.63 One year: 8.92 |
| Support: |
Support1: 5.49  Support2: 4.84 |
| Resistance: |
Resistance1: 6.53 Resistance2: 7.63 |
| Pivot: |
6.15  |
| Moving Average: |
MA(5): 6.24 MA(20): 6.17
MA(100): 5.79 MA(250): 7.3 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 54.9 %D(3): 56.3 |
| RSI: |
RSI(14): 62.5 |
| 52-week: |
High: 14.25 Low: 3.4 |
| Average Vol(K): |
3-Month: 34 (K) 10-Days: 16 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SLDB ] has closed below upper band by 31.2%. Bollinger Bands are 75.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.38 - 6.43 |
6.43 - 6.46 |
|
Low:
|
6.05 - 6.1 |
6.1 - 6.13 |
|
Close:
|
6.19 - 6.26 |
6.26 - 6.31 |
|
Company Description |
|
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Thu, 01 Jun 2023
Solid Biosciences to Participate at the Jefferies Healthcare Conference - Marketscreener.com
Sun, 28 May 2023
K2 Principal Fund L.P. Has $1.84 Million Holdings in Solid ... - MarketBeat
Mon, 22 May 2023
Solid Biosciences to Participate at the Barclays Gene Editing ... - Solid Biosciences
Tue, 16 May 2023
Solid Biosciences to Present at the American Society of Gene and ... - Solid Biosciences
Thu, 11 May 2023
Solid Biosciences Provides First Quarter Business Update and ... - Solid Biosciences
Mon, 08 May 2023
Solid Biosciences to Present at JMP Securities Life Sciences ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
20 (M) |
|
% Held by Insiders
|
7.42e+006 (%) |
|
% Held by Institutions
|
0.4 (%) |
|
Shares Short
|
45 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.0353e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
717.1 |
|
Return on Equity (ttm)
|
-30.3 |
|
Qtrly Rev. Growth
|
6.17e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-33.2 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-8.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-99 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.19 |
|
Price to Cash Flow
|
0.98 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
40700 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
